Skip to content

The Role of Hypertonic Dextrose Spray as Endoscopic Topical Hemostatic Agent for Acute Non-Variceal Upper GI Bleeding

The Role of Hypertonic Dextrose Spray as Endoscopic Topical Hemostatic Agent for Acute Non-Variceal Upper Gastrointestinal Bleeding: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04979273
Enrollment
66
Registered
2021-07-28
Start date
2021-03-01
Completion date
2021-12-31
Last updated
2021-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro Intestinal Bleeding

Brief summary

This study is conducted to evaluate the effectivity of hypertonic dextrose spray as an endoscopic topical hemostatic agent, compared to conventional agent (adrenaline injection, followed by hemoclip or thermocoagulation), in patients with acute non-variceal upper GI bleeding.

Interventions

DRUGDextrose 40 % in Water

injection of adrenaline 1:20.000, followed by dextrose 40% spray

injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip

Thermocoagulation

PROCEDUREHemoclip

Hemoclip

Sponsors

Dr Cipto Mangunkusumo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with acute non-variceal upper gastrointestinal bleeding caused by peptic or duodenal ulcer, polyps, tumors or malignancy * Patients consented to study participation

Exclusion criteria

* Patients with thrombocytopenia (thrombocyte count \<100.000 cells/ul) and other forms of coagulopathy

Design outcomes

Primary

MeasureTime frameDescription
Hemostatic success5 minuteNumber of participants whose bleeding stops within five minutes after intervention is given. Outcome is assessed by independent assessor (not the endoscopy operator), who also attend the endoscopy session and could observe whether the bleeding stops.

Secondary

MeasureTime frameDescription
Re-bleeding7 daysNumber of participants who experience decrease in hemoglobin \>1g/dl or need additional hemostatic endoscopy within one week after intervention

Countries

Indonesia

Contacts

Primary ContactHasan Maulahela, MD
hasanmaulahela@yahoo.com+6281283602549

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026